Evidence supporting the use of: Cysteine compounds (unspecified)
For the health condition: Chronic Obstructive Pulmonary Disorder

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Cysteine compounds, particularly N-acetylcysteine (NAC), are supported by scientific evidence for use in Chronic Obstructive Pulmonary Disease (COPD). NAC is a precursor to the antioxidant glutathione and has mucolytic (mucus-thinning) properties, which can be beneficial in COPD, a disease characterized by oxidative stress and excessive mucus production in the airways. Several randomized controlled trials and meta-analyses have investigated NAC in COPD patients. Results indicate that long-term oral NAC at doses of 600-1200 mg/day can modestly reduce the frequency of exacerbations and may improve symptoms such as cough and sputum production, particularly in patients not using inhaled corticosteroids. However, the evidence is mixed regarding its effects on lung function or quality of life, and some guidelines recommend its use only in select patients with frequent exacerbations despite optimal inhaled therapy. Other cysteine compounds, like L-cysteine, are less well studied for COPD. Overall, the use of NAC in COPD is scientifically validated, though the effect size is modest and its use is not universally recommended for all COPD patients.

More about Cysteine compounds (unspecified)
More about Chronic Obstructive Pulmonary Disorder

Products containing Cysteine compounds (unspecified)

We currently have no products on Caring Sunshine that contain this ingredient.